Recovery · In Clinical Trials
Nexagon (Gap Junction Peptide)
No lawful US pathway
01 · Overview
Nexagon (lufepirsen) is not a peptide: it is a connexin43-specific antisense oligodeoxynucleotide, a short strand of DNA that transiently blocks production of the gap junction protein connexin43 (PMID 22797940). Reducing connexin43 at wound sites early in healing reduced inflammatory cell recruitment and accelerated keratinocyte and fibroblast proliferation and migration in animal wounds (PMID 17158921).
It is applied topically in a gel, and current development focuses on persistent corneal epithelial defects (PMID 40265394).
02 · Research summary & key findings
In the first human use, connexin43 antisense applied to five eyes with severe ocular burns and nonhealing epithelial defects reduced inflammation within one to two days, and all five eyes achieved complete corneal re-epithelialization (PMID 22797940). Phase 2 studies in venous leg ulcers and corneal defects have been registered, but controlled efficacy results have not been published in peer-reviewed journals, and a randomized phase 2 trial in persistent corneal epithelial defects is recruiting.
03 · Regulatory status
Nexagon (Gap Junction Peptide) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Nexagon (Gap Junction Peptide) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 3 FDA-approved compounds in Recovery
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for injury recovery and tissue repair?
Nexagon (Gap Junction Peptide) is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on injury recovery and tissue repair, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Topical
References
- [1]Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration J Cell Sci, 2006. PMID 17158921
- [2]Regulation of connexin43 gap junction protein triggers vascular recovery and healing in human ocular persistent epithelial defect wounds J Membr Biol, 2012. PMID 22797940
- [3]Emerging Treatments for Persistent Corneal Epithelial Defects Vision (Basel), 2025. PMID 40265394
Primary literature
- PubMed: "Nexagon"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Nexagon"
Registered interventional and observational studies, including status and phase.
- PubChem: "Nexagon"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Recovery
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.